This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The long term goal of the work in my laboratory is to understand the multiple roles that the Notch signaling pathway plays during embryonic development in mammals, and the connections between this pathway and the development of congenital human disease syndromes. The components of the Notch signaling pathway constitute an evolutionarily-conserved set of proteins that controls cell fate specification in numerous tissues, and is essential for proper embryonic development in organisms as diverse as insects, nematodes and mammals. In Drosophila, the Notch gene encodes a large transmembrane receptor that, at the extracellular surface of a cell, interacts with membrane-bound ligands encoded by the Delta and Serrate genes. In mammals, four Notch family receptors have been described: Notch1, 2, 3 and 4. Five genes encoding ligands for the Notch family of receptors have been described: two of the Jagged/Serrate family (Jag1 and Jag2) and three of the Delta-like family (Dll1, Dll3 and Dll4). While previous work has revealed a role for Notch signaling in regulating myogenesis and skeletal muscle satellite cell activation, no progressive Notch signaling-dependent myopathy model has been described. We have found that mice doubly heterozygous for mutations of the Notch ligands Dll1 and Jag2 (Dll1/Jag2 +/- mice) exhibit a progressive postnatal myopathy that preferentially affects epaxial muscles of the back. This model provides a valuable new resource for studying the physiological role of Notch signaling during skeletal muscle function in mammals.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR018789-09
Application #
8360272
Study Section
Special Emphasis Panel (ZRR1-RI-6 (01))
Project Start
2011-06-01
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
9
Fiscal Year
2011
Total Cost
$123,920
Indirect Cost
Name
Maine Medical Center
Department
Type
DUNS #
071732663
City
Portland
State
ME
Country
United States
Zip Code
04102
Duarte, Christine W; Black, Adam W; Lucas, F Lee et al. (2017) Cancer incidence in patients with hereditary hemorrhagic telangiectasia. J Cancer Res Clin Oncol 143:209-214
Caron, Jennifer M; Ames, Jacquelyn J; Contois, Liangru et al. (2016) Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen Epitope. Am J Pathol 186:1649-61
Stohn, J Patrizia; Wang, Qiaozeng; Siviski, Matthew E et al. (2015) Cthrc1 controls adipose tissue formation, body composition, and physical activity. Obesity (Silver Spring) 23:1633-42
Ufkin, Melanie L; Peterson, Sarah; Yang, Xuehui et al. (2014) miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res 38:402-10
He, Qing; Yang, Xuehui; Gong, Yan et al. (2014) Deficiency of Sef is associated with increased postnatal cortical bone mass by regulating Runx2 activity. J Bone Miner Res 29:1217-31
Motyl, Katherine J; Bishop, Kathleen A; DeMambro, Victoria E et al. (2013) Altered thermogenesis and impaired bone remodeling in Misty mice. J Bone Miner Res 28:1885-97
Urs, Sumithra; Henderson, Terry; Le, Phuong et al. (2012) Tissue-specific expression of Sprouty1 in mice protects against high-fat diet-induced fat accumulation, bone loss and metabolic dysfunction. Br J Nutr 108:1025-33
Sathyanarayana, Pradeep; Dev, Arvind; Pradeep, Anamika et al. (2012) Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2. Blood 119:5522-31
Motyl, Katherine J; Dick-de-Paula, Ingrid; Maloney, Ann E et al. (2012) Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. Bone 50:490-8
Favreau, Amanda J; Cross, Erin L; Sathyanarayana, Pradeep (2012) miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia. Am J Hematol 87:442-6

Showing the most recent 10 out of 102 publications